Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate
Lantern Pharma (LTRN) - Market capitalization
Lantern Pharma (@LanternPharma) / Twitter
Irwin case study: Lantern Pharma | IR Magazine
Taking on an IPO: How Lantern Pharma got it done amid COVID-19 — and the opportunities ahead - Dallas Business Journal
Lantern Pharma Inc. (Nasdaq: LTRN) | LinkedIn
Lantern Pharma Joins Genomics England to Advance Their Precision Oncology Platform | Business Wire
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting | BioSpace